Added to YB: 2026-07-22
Pitch date: 2026-07-19
NKTR [bullish]
Nektar Therapeutics
+1.98%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
Market Cap
$2.3B
Pitch Price
$67.34
Price Target
145.00 (+124%)
Dividend
N/A
EV/EBITDA
-14.87
P/E
-8.44
EV/Sales
30.88
Sector
Pharmaceuticals
Category
value
Show full summary:
Nektar Therapeutics: (Rez)t and Forget
NKTR: IL-2 Treg biologic Rezpeg in AD/AA. Ph2b AD data strong (61% EASI, Q12W maintenance, clean safety); AA matches low-dose JAK w/o black box as OX40/OX40L class dies on Kaposi risk. $1.1B cash post-raise. EV ~$1.5B. PT $145 vs $68, 112% upside; Lilly litigation (Sep'26) free option.
Read full article (20 min)